BIOAEGIS THERAPEUTICS
BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare ... orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
BIOAEGIS THERAPEUTICS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2011-01-01
Address:
Morristown, New Jersey, United States
Country:
United States
Website Url:
http://www.bioaegistherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
1(203) 952-6373
Email Addresses:
[email protected]
Total Funding:
42.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Current Employees Featured
Founder
Official Site Inspections
http://www.bioaegistherapeutics.com Semrush global rank: 4.78 M Semrush visits lastest month: 1.92 K
- Host name: 192.72.153.160.host.secureserver.net
- IP address: 160.153.72.192
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "BioAegis Therapeutics"
Protein Replacement Therapy - Contact Us | BioAegis Therapeutics
Sep 12, 2024 Organization Role Scientist/Academic Media Investor Other. Message SEND. Stay informed of our latest discoveries and news. EMAIL SUBSCRIBE. GENERAL …See details»
BioAegis Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 1(203) 952-6373 BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role …See details»
BioAegis Therapeutics - PitchBook
Www.bioaegistherapeutics.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. Commercialization Center for Innovative …See details»
Bioaegis Therapeutics, Inc. Company Profile | Morristown, NJ ...
Find company research, competitor information, contact details & financial data for Bioaegis Therapeutics, Inc. of Morristown, NJ. Get the latest business insights from Dun & Bradstreet.See details»
BioAegis Therapeutics, Inc. | LinkedIn
BioAegis Therapeutics, Inc. Biotechnology Research North Brunswick, New Jersey 2,097 followers Commercializing a key component of the immune system, #Gelsolin, for infectious, …See details»
Chief Executive Officer, Susan L. Levinson, PhD.
She began her career at Novartis as Director of Licensing for the former Ciba-Geigy organization, where she led licensing strategy and negotiations within the Bone, Inflammation, Pulmonary and Oncology therapeutic areas. She began …See details»
BioAegis Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Www.bioaegistherapeutics.com. Holding Company | 2011 | New Jersey, United States | < 10 | www.bioaegistherapeutics.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. …See details»
BioAegis Therapeutics - VentureRadar
"BioAegis Therapeutics Inc. is a clinical stage, private company whose mission is to exploit a key component of the body’s innate immune system to prevent adverse outcomes of diseases …See details»
BioAegis Therapeutics, Inc. Information - RocketReach
What is the annual revenue of BioAegis Therapeutics, Inc.? The BioAegis Therapeutics, Inc. annual revenue was $1 million in 2024.See details»
BioAegis Therapeutics - Craft
BioAegis Therapeutics is a company focused on developing therapies for infectious, inflammatory, and degenerative diseases. It offers protein replacement therapies based on the endogenous …See details»
BioAegis Therapeutics - Overview, News & Similar companies
BioAegis Therapeutics contact info: Phone number: (973) 539-4552 Website: www.bioaegistherapeutics.com What does BioAegis Therapeutics do? BioAegis Theraputics is …See details»
BioAegis Therapeutics - Products, Competitors, Financials, …
Bioaegistherapeutics.com. Overview & Products; Financials; People; Founded Year 2011. Stage Unattributed - II | Alive. Total Raised $41.1M. Last Raised $22M | 3 yrs ago. Mosaic Score. …See details»
BioAegis Therapeutics
BioAegis Therapeutics is developing novel protein replacement therapies for infectious, inflammatory and degenerative diseases. Chronic inflammation underpins many diseases and …See details»
BioAegis Therapeutics Careers | Join Our Team Today
Oct 17, 2024 BioAegis is a science-driven organization focused on developing innovative high-value therapies and diagnostics to improve and save lives. The Company offers a …See details»
February 2022: BioAegis Therapeutics Announces Appointment of …
Feb 17, 2022 New board members bring a wealth of financial, strategy and global health expertise. NORTH BRUNSWICK, N.J., February 17, 2022 (GLOBE NEWSWIRE) — BioAegis …See details»
Articles about BioAegis Therapeutics - BioSpace
Apr 13, 2023 37 articles about BioAegis Therapeutics. BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute …See details»
BioAegis Therapeutics - VentureRadar
Similar Companies: Foreseen Biotech Unknown Privately Held Foreseen Biotech was founded in 2021 by the leading MS-spec proteomics expert with >20 years' experiences, and a group of …See details»
March 2022: BioAegis Therapeutics Completes $22 Million …
Mar 22, 2022 Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., …See details»
COVID-19 Response - BioAegis Therapeutics
The randomized, double-blind, placebo-controlled, proof-of-concept trial of rhu-pGSN added to standard of care will assess the efficacy (survival without organ failure on Day 14) of three …See details»